SARS-CoV-2 humoral immune response in patients with cardiovascular risk factors: the COmmunity Cohort Study protocol

被引:4
|
作者
Bachelet, Vivienne C. [1 ]
Silva-Ayarza, Ignacio [1 ,2 ]
Lizana, Francisca J. [1 ]
Gomolan, Patricio [1 ]
Silva-Villalobos, Diego [1 ]
Navarrete, Maria S. [1 ]
机构
[1] Univ Santiago de Chile, Escuela Med, Santiago, Chile
[2] Hosp Barros Luco, Dept Infect Dis, Santiago, Chile
来源
BMJ OPEN | 2022年 / 12卷 / 05期
关键词
ANTIBODY-RESPONSES; DISEASE; DURABILITY; BNT162B2; COVID-19; KINETICS; VOCS;
D O I
10.1136/bmjopen-2022-061345
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction The COmmunity Cohort Study aims to determine, after natural exposure to SARS-CoV-2 or anti-SARS-CoV-2 vaccines deployed in Chile to prevent COVID-19 in the context of the current pandemic, the strength and duration of detectable neutralising antibodies in adult ambulatory primary care patients with cardiovascular risk factors. Methods and analysis We will set up a community-based longitudinal, prospective cohort study. The study will be conducted in two public outpatient clinics located in the southern district of Santiago, Chile. We expect to begin recruitment in the second quarter of 2022. Each patient will be followed up for at least 1 year after inclusion in the cohort. The eligible population will be adult patients registered in the Cardiovascular Health Programme. Exposure in this study is defined as any event where participants have contact with SARS-CoV-2 antigens from natural exposure or vaccination. The primary outcomes are seroconversion and strength and duration of the neutralising IgG antibodies to SARS-CoV-2. Secondary outcomes are any COVID-19-related event or intercurrent morbidities or death. Data will be collected by extracting serial blood samples and administering a questionnaire at the first face-to-face contact and monthly follow-up time points. The sample size estimated for this study is 1060. We will characterise the cohort, determine the seroprevalence rate of neutralising antibodies at baseline and determine the rates of antibody decline using a longitudinal mixed-effects model. Ethics and dissemination The Scientific Ethics Committee of the South Metropolitan Health Care Service approved the study protocol (Memorandum No 191/2021). We will present the results in two peer-reviewed publications and national and international professional and academic meetings. We will organise seminars with relevant stakeholders and hold town hall meetings with the local community. We will set up a COmmunity Cohort Study website at www.communitystudy.cl to disseminate the study purpose, research team and milestones.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Humoral immune response after different SARS-CoV-2 vaccination regimens
    Rose, Ruben
    Neumann, Franziska
    Grobe, Olaf
    Lorentz, Thomas
    Fickenscher, Helmut
    Krumbholz, Andi
    BMC MEDICINE, 2022, 20 (01)
  • [22] OBSERVATIONAL STUDY OF HUMORAL RESPONSE TO SARS-COV-2 MRNA VACCINATION IN A COHORT OF RENAL TRANSPLANTS COMPARED TO PRIMARY IMMUNE DEFICIENCY
    Rahima, Hashemi
    Shivakumar, Kunigal
    Nicholas, Claire
    Bhole, Malini
    Webber, Caroline
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2023, 38 : I971 - I972
  • [23] Immune response in SARS-CoV-2
    Luis Aguilar-Shea, Antonio
    Gallardo Mayo, Cristina
    JOURNAL OF FAMILY MEDICINE AND PRIMARY CARE, 2020, 9 (09) : 5074 - 5075
  • [24] Longitudinal SARS-CoV-2 humoral response in MS patients with and without SARS-CoV-2 infection prior to vaccination
    van Dam, Koos P. J.
    Hogenboom, Laura
    Stalman, Eileen W.
    Kummer, Laura Y. L.
    Steenhuis, Maurice
    Keijser, Jim B. D.
    ten Brinke, Anja
    van Ham, S. Marieke
    Kuijpers, Taco W.
    Rispens, Theo
    Wieske, Luuk
    Eftimov, Filip
    Strijbis, Eva M.
    Killestein, Joep
    van Kempen, Zoe L. E.
    FRONTIERS IN NEUROLOGY, 2022, 13
  • [25] SARS-CoV-2 Antibody Seroprevalence and Humoral Response to Vaccination in Patients Undergoing Maintenance Hemodialysis: A Prospective Cohort Study
    Senthilkumaran, Guhan
    Rajarathinam, Vaishanavi D.
    Govindarajan, Srinivasaraman
    Jibia, V. S.
    Balasubramanian, Chelvamalai M.
    Devaraju, Prem K.
    Murugesan, Vinoj
    Shankar, P.
    Lamech, Tanuj M.
    Arumugam, Venkatesh
    Gopalakrishnan, Natarajan
    INDIAN JOURNAL OF NEPHROLOGY, 2024, 34 (02) : 129 - 133
  • [26] Immunogenicity and risk factors for poor humoral immune response to SARS-CoV-2 vaccine in patients with autoimmune hepatitis: a systematic review and meta-analysis
    Tian, Zhaoxu
    Chen, Yonghua
    Yao, Yingxin
    Chen, Lihua
    Zhu, Xiakai
    Shen, Zhaocong
    Yang, Shanwei
    Jin, Hangbin
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2024, 116 (12) : 671 - 679
  • [27] Immune Response to SARS-CoV-2 in an Asymptomatic Pediatric Allergic Cohort
    Marsteller, Nathan L.
    Fregoso, Diana J.
    Morphew, Tricia L.
    Randhawa, Inderpal S.
    ANTIBODIES, 2021, 10 (02)
  • [28] SARS-CoV-2 Humoral Immunity in a Cohort of Patients with Head and Neck Carcinoma
    Marutescu, L. G.
    Enea, A. G.
    Dragu, E.
    Popa, M.
    Costea, D. A.
    Neculae, M.
    Chifiriuc, C. M.
    Codrici, E.
    Bertesteanu, S. G-V
    Ristoiu, V.
    Lazar, V.
    Grigore, R.
    Ancuta, P.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2023, 25 (06): : S48 - S48
  • [29] Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls
    Nemeth, Dora
    Vago, Hajnalka
    Tothfalusi, Laszlo
    Ulakcsai, Zsuzsanna
    Becker, David
    Szabo, Zsofia
    Rojkovich, Bernadett
    Gunkl-Toth, Lilla
    Merkely, Bela
    Nagy, Gyorgy
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [30] Humoral Immune Response to BBV152 (Covaxin) SARS-CoV-2 Vaccine in Patients on Hemodialysis
    Vijayaraghavan, Radha
    Senthilkumar, P. K.
    Velu, Kannan B.
    Viswanathan, Ramasubramanian
    Balasundaram, Karthikeyan
    Anand, S. Murugesh
    INDIAN JOURNAL OF NEPHROLOGY, 2023, 33 (05) : 395 - 397